LNP023

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Trial Timeline

Oct 28, 2025 → Dec 19, 2031

NCT ID

NCT06934967

About LNP023

LNP023 is a phase 3 stage product being developed by Novartis for Paroxysmal Nocturnal Hemoglobinuria (PNH). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06934967. Target conditions include Paroxysmal Nocturnal Hemoglobinuria (PNH).

What happened to similar drugs?

0 of 20 similar drugs in Paroxysmal Nocturnal Hemoglobinuria (PNH) were approved

Approved (0) Terminated (4) Active (16)

🔄Crovalimab + EculizumabChugai PharmaceuticalPhase 3

🔄EculizumabAstraZenecaPhase 3

🔄DanicopanAstraZenecaPhase 3

🔄Iptacopan (LNP023)NovartisPhase 3

🔄IptacopanNovartisPhase 3

🔄LNP023 + Eculizumab + RavulizumabNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06934967	Phase 3	Recruiting	Oct 28, 2025	Dec 19, 2031	Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT06931691	Pre-clinical	Recruiting	Jun 10, 2025	Apr 20, 2027	Paroxysmal Nocturnal Hemoglobinuria
NCT04557462	Phase 3	Recruiting	Sep 20, 2021	Oct 25, 2032	Primary IgA Nephropathy
NCT03955445	Phase 3	Recruiting	Oct 3, 2019	May 30, 2036	C3 Glomerulopathy
NCT03896152	Phase 2	Completed	Apr 5, 2019	Feb 9, 2022	Paroxysmal Nocturnal Hemoglobinuria
NCT03832114	Phase 2	Completed	Feb 20, 2019	Apr 23, 2021	Glomerulonephritis
NCT03373461	Phase 2	Completed	Feb 7, 2018	Jun 22, 2021	IgA Nephropathy

Competing Products

20 competing products in Paroxysmal Nocturnal Hemoglobinuria (PNH)

See all competitors

Product	Company	Stage	Hype Score
Crovalimab + Eculizumab	Chugai Pharmaceutical	Phase 3	44
Crovalimab + Placebo	Chugai Pharmaceutical	Phase 1/2	36
Crovalimab + Eculizumab	Chugai Pharmaceutical	Phase 3	44
Ravulizumab	AstraZeneca	Pre-clinical	30
Eculizumab	AstraZeneca	Phase 3	40
Danicopan	AstraZeneca	Phase 3	47
LNP023	Novartis	Pre-clinical	33
Iptacopan (LNP023)	Novartis	Phase 3	40
iptacopan	Novartis	Phase 2	35
LNP023	Novartis	Phase 2	35
Iptacopan	Novartis	Pre-clinical	30
Iptacopan	Novartis	Phase 3	40
LNP023 + Eculizumab + Ravulizumab	Novartis	Phase 3	40
LFG316 + LNP023	Novartis	Phase 2	35
Iptacopan	Novartis	Phase 3	44
Crovalimab	Roche	Phase 3	44
ABP 959 + Eculizumab	Amgen	Phase 3	40
Pegcetacoplan	Swedish Orphan Biovitrum	Pre-clinical	33
BMS-919373 + Placebo (Matching with BMS-919373)	Bristol Myers Squibb	Phase 2	27
Humanized anti-Factor Bb monoclonal antibody + Placebo	Sanofi	Phase 1	29